Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions

Clinical Biochemistry

Volumn 43, Issue 7-8, 2010, Pages 666-670

  Riondino, Silvia ^a   Martini, Francesca ^a   La Farina, Francesca ^a   Spila, Antonella ^a   Guadagni, Fiorella ^a   Ferroni, Patrizia ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Aspirin; Light transmission aggregometry; Platelets; SCD40L; SP selectin

Indexed keywords

ACETYLSALICYLIC ACID; CD40 LIGAND; CITRIC ACID; PADGEM PROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; CD40 LIGAND; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 77951204688     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.021     Document Type: Article

References (40)

1. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., Cavusoglu E., Marmur J.D. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb. Haemost. 2003, 90:377-384.
2. Paulie S., Ehlin-Henriksson B., Mellstedt H., Koho H., Ben-Aissa H., Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother. 1985, 20:23-28.
3. Clark E.A., Ledbetter J.A. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:4494-4498.
4. Noelle R.J., Roy M., Shepherd D.M., Stamenkovic I., Ledbetter J.A., Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:6550-6554.
5. Yellin M.J., Winikoff S., Fortune S.M., et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J. Leukoc. Biol. 1995, 58:209-216.
6. Fries K.M., Sempowski G.D., Gaspari A.A., Blieden T., Looney R.J., Phipps R.P. CD40 expression by human fibroblasts. Clin. Immunol. Immunopathol. 1995, 77:42-51.
7. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA. 1995, 9:4342-4346.
8. Yellin M.J., Brett J., Baum D., et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J. Exp. Med. 1995, 182:1857-1864.
9. Ferroni P., Santilli F., Guadagni F., Basili S., Davì G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr. Med. Chem. 2007, 14:2170-2180.
10. Basili S., Santilli F., Ferroni P., Dav̀ G. CD40/CD40L system and vascular disease. Intern. Emerg. Med. 2007, 2:256-268.
11. Sugiura T., Kawaguchi Y., Harigai M., et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J. Immunol. 2000, 164:6593-6600.
12. Bereznaya N.M., Chekhun V.F. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp. Oncol. 2007, 29:2-12.
13. Tousoulis D., Antoniades C., Koumallos N., Stefanadis C. Proinflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev. 2006, 17:225-233.
14. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Kaski J.C. Soluble CD40 ligand: interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb. Res. 2009, 123:617-621.
15. Manenti E.R., Bodanese L.C., Camey S.A., Polanczyk C.A. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin. Cardiol. 2006, 29:405-410.
16. Turker S., Guneri S., Akdeniz B., et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am. J. Cardiol. 2006, 97:198-202.
17. Ferro D., Loffredo L., Polimeni L., et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2763-2768.
18. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 2003, 348:1104-1111.
19. Garlichs C.D., Kozina S., Fateh-Moghadam S., et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418.
20. Blake G.J., Ostfeld R.J., Yucel E.K., et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler. Thromb. Vasc. Biol. 2003, 23:11-14.
21. Balla J., Magyar M.T., Bereczki D., et al. Serum levels of platelet released CD40 ligand are increased in early onset occlusive carotid artery disease. Dis. Markers 2006, 22:133-140.
22. Novo S., Basili S., Tantillo R., et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 2005, 36:673-675.
23. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch. Intern. Med. 1993, 153:154-183.
24. Classification of hyperlipidemias and hyperlipoproteinemias. Circulation 1972, 45:501-508. WHO memorandum.
25. Tousoulis D., Antoniades C., Nikolopoulou A., et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur. J. Clin. Invest. 2007, 37:623-628.
26. Roselli M., Mineo T.C., Basili S., et al. Soluble CD40 ligand (sCD40L) plasma levels in lung cancer. Clin. Cancer Res. 2004, 10:610-614.
27. Mason P.J., Chakrabarti S., Albers A.A., et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am. J. Cardiol. 2005, 96:1365-1369.
28. Choudhury A., Chung I., Panja N., Patel J., Lip G.Y.H. Soluble CD40 ligand, platelet surface CD40 ligand and total platelet CD40 ligand in atrial fibrillation. Chest 2008, 134:574-581.
29. Henn V., Steinbach S., Buchner K., et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporarily limited by coexpressed CD40. Blood 2001, 98:1047-1054.
30. Hermann A., Rauch B.H., Braun M., Schrö K., Weber A.A. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001, 12:74-82.
31. Nannizzi-Alaimo L., Alves V.L., Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003, 107:1123-1128.
32. Ferroni P., Martini F., Riondino S., et al. Soluble P-selectin as a marker of in vivo platelet activation. Clin. Chim. Acta 2009, 399:88-91.
33. Pernerstorfer T., Eichler H.G., Stohlawetz P., Speiser W., Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis 2001, 155:389-393.
34. Jilma B., Blann A., Pernerstorfer T., et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am. J. Respir. Crit. Care Med. 1999, 159:857-863.
35. Ivandic B.T., Spanuth E., Haase D., Lestin H.G., Katus H.A. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin. Chem. 2007, 53:1231-1234.
36. Varo N., Nuzzo R., Natal C., Libby P., SchÖnbeck U. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin. Sci. (Lond.) 2006, 111:341-347.
37. Ahn E.R., Lander G., Jy W., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb. Res. 2004, 114:143-148.
38. Lengellé J., Panopoulos E., Betsou F. Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. Cytokine 2008, 44:275-282.
39. Thom J., Gilmore G., Yi Q., Hankey G.J., Eikelboom J.W. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J. Thromb. Haemost. 2004, 2:2067-2069.
40. Weber M., Rabenau B., Stanisch M., et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin. Chem. 2006, 52:888-891.